title: Losartan in Cushing's syndrome.
abstract: Eleven patients with Cushing's syndrome were included in the study. They maintained their usual sodium intake and received a single oral dose of 50 mg of the angiotensin II antagonist receptor losartan for 3 days. Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity. Both systolic and diastolic blood pressure decreased independently of baseline level of active renin. The relationship between kallikrein and renin-angiotensin system are discussed.
authors.affiliation: Clinical Center of Endocrinology and Gerontology, Medical University, Sofia, Bulgaria.
authors.forename: S
authors.initials: S
authors.lastname: Zacharieva
authors.forename: M
authors.initials: M
authors.lastname: Orbetzova
authors.forename: E
authors.initials: E
authors.lastname: Natchev
authors.forename: J
authors.initials: J
authors.lastname: Vergilova
authors.forename: M
authors.initials: M
authors.lastname: Andrewa
authors.forename: M
authors.initials: M
authors.lastname: Wipperrnann
authors.forename: S
authors.initials: S
authors.lastname: Torbova
authors.forename: D
authors.initials: D
authors.lastname: Tzingilev
authors.forename: P
authors.initials: P
authors.lastname: Angelova-Gateva
mesh_terms: D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003480:Cushing Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D016234:Kallikrein-Kinin System / Q000187:drug effects; D007610:Kallikreins / Q000032:analysis*; D019808:Losartan / Q000008:administration & dosage / Q000627:therapeutic use*; D012083:Renin / Q000097:blood*; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D007610:Kallikreins; D012083:Renin; D019808:Losartan